黄芪注射液对早期糖尿病肾病患者血小板功能和血浆内皮素的影响

目的：了解黄芪注射液对早期糖尿病肾病的治疗作用。方法：早期糖尿病肾病患者136例，随机分为常规治疗（R1）组50例和黄芪治疗（R2）组86例，治疗疗程3周，用放射免疫法和酶联免疫吸附方法，分别测定糖尿病肾病患者药物治疗前后内皮素－1（ET－1），24h尿白蛋白排泄率（uAER）和血小板颗粒膜蛋白（GMP－140），6－酮－前列腺素F1α（6－Keto-PGF1α)及血栓素B2（TXB2）；并选择26名健康人为对照（N）组。结果：糖尿病肾病患者血浆ET－1、GMP－140、TXB2水平显著高于健康人，而6－Keto-PGF1α则低于健康人；治疗后血浆ET－1水平降低，GMP－140、TXB2和uAER显著降低。结论：糖尿病肾病的发生和发展可能与血浆内皮素水平改变和血小板功能的改变有关，黄芪可改善早期糖尿病患者血小板功能和血浆内皮素水平。

Effect of Astragalus Injection on Platelet Function and Plasma Endothelin in Patients with Early Stage Diabetic Nephropathy

OBJECTIVE: To study the therapeutic effect of Astragalus injection (AI) in treating early stage diabetic nephropathy (DN) patients. METHODS: The total of 136 early diabetic nephropathy patients were randomly divided into two groups, 50 cases in the conventional treated group and 86 in the AI treated group, the therapeutic course being 3 weeks. Levels of plasma endothelin-1 (ET-1), 24 hrs urinary albumin excretion rate (uAER), and platelet granule membrane protein (GMP-140), 6-keto-prostaglandin F1 alpha(6-keto-PGF1 alpha), and thromboxane B2(TXB2) before and after treatment were determined by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) respectively. Moreover, the above-mentioned criteria in 26 healthy subjects were also measured for control. RESULTS: The plasma ET-1, GMP-140, TXB2 and uAER levels in DN patients were higher, but 6-keto-PGF1 alpha level was lower than those in healthy subjects. The above elevated criteria in DN patients could be lowered by AI treatment. CONCLUSION: The pathogenesis and development of DN might be closely associated with the changes of plasma ET-1 level and platelet function. Astragalus could improve the above-mentioned changes in patients of early stage DN.